Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.

The diagnosis of LTBI is primarily based on the results of the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA), also known as the QuantiFERON-TB Gold In-Tube (GFT-GIT) test.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent in ...

covers important innovations in QuantiFERON-TB Gold Plus that is used worldwide for TB detection. "Protecting our intellectual property is essential to ensuring continued innovation in infectious ...

Tracking targeted drug delivery is often a challenge due to limitations in current imaging techniques. A recent study by ...

Tracking targeted drug delivery is often a challenge due to limitations in the current imaging techniques. A recent study reports a breakthrough imaging technique that allows direct and highly ...

Join American Rifleman staff on the range in this episode to learn about Mossberg’s International Gold Reserve model, the ...